Skip to main content
    S

    Si-Bone Inc (SIBN)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $23.44
    -0.70 (-2.90%)

    Market Cap: $1.06B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Si-Bone Inc (SIBN) Earnings: Report Dates and Results

    Updated Nov 2, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Si-Bone reported EPS of -$0.08, above the -$0.13 estimate. It beat the EPS estimate in each of the last 17 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    64%(21/33)
    Avg Surprise
    +10.91%
    Streak
    17 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.07
    Range-$0.09 - -$0.05
    11 analysts
    Revenue Consensus
    $69.24M
    Range$66.35M - $72.03M
    11 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.10
    Range-$0.15 - -$0.06
    5 analysts
    EPS Revisions
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.10-2.3%
    60d ago-$0.10-2.3%
    30d ago-$0.10-2.3%
    7d ago-$0.10-2.3%
    Current-$0.10
    Revenue Consensus
    $62.38M
    Range$60.70M - $64.04M
    6 analysts

    Next Report

    SIBN's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    SIBN Earnings Call

    The latest SIBN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 33 quarters below that had an estimate, SIBN beat 21, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $55.70M, up 14.5% from $48.66M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.08-$0.13-$0.17 - -$0.08+38.46%BeatN/A8N/ANov 2, 2026$55.70M
    Jun 30, 2026-$0.09-$0.15-$0.17 - -$0.12+40.00%BeatN/A82 up, 1 downAug 3, 2026$56.01M
    Mar 31, 2026-$0.10-$0.19-$0.24 - -$0.16+47.37%BeatN/A71 up, 5 downMay 11, 2026$52.59M
    Dec 31, 2025-$0.04-$0.13-$0.14 - -$0.11+69.23%BeatN/A90 up, 2 downFeb 23, 2026$56.35M
    Sep 30, 2025-$0.11-$0.16-$0.20 - -$0.14+31.25%BeatN/A84 up, 0 downNov 10, 2025$48.66M
    Jun 30, 2025-$0.14-$0.18-$0.23 - -$0.15+22.22%BeatN/A86 up, 1 downAug 4, 2025$48.63M
    Mar 31, 2025-$0.15-$0.22-$0.27 - -$0.18+31.82%BeatN/A82 up, 3 downMay 5, 2025$47.29M
    Dec 31, 2024-$0.11-$0.13-$0.18 - -$0.01+18.09%BeatN/A70 up, 1 downFeb 24, 2025$49.00M
    Sep 30, 2024-$0.16-$0.24-$0.29 - -$0.20+33.33%BeatN/A90 up, 0 downNov 12, 2024$40.34M
    Jun 30, 2024-$0.22-$0.28-$0.30 - -$0.24+21.43%BeatN/A90 up, 0 downAug 5, 2024$39.97M
    Mar 31, 2024-$0.27-$0.31-$0.37 - -$0.26+12.90%BeatN/A90 up, 0 downMay 6, 2024$37.87M
    Dec 31, 2023-$0.27-$0.28-$0.31 - -$0.23+3.57%BeatN/A80 up, 0 downFeb 26, 2024$38.86M
    Sep 30, 2023-$0.25-$0.34-$0.40 - -$0.29+26.47%BeatN/A80 up, 0 downNov 6, 2023$34.01M
    Jun 30, 2023-$0.30-$0.40-$0.48 - -$0.30+25.00%BeatN/A81 up, 0 downAug 7, 2023$33.30M
    Mar 31, 2023-$0.32-$0.42-$0.45 - -$0.36+23.81%BeatN/A70 up, 0 downMay 1, 2023$32.71M
    Dec 31, 2022-$0.32-$0.40-$0.46 - -$0.32+20.00%BeatN/A81 up, 0 downFeb 27, 2023$31.95M
    Sep 30, 2022-$0.41-$0.47-$0.53 - -$0.44+12.77%BeatN/A80 up, 0 downNov 7, 2022$26.43M
    Jun 30, 2022-$0.54-$0.49N/A-10.20%MissN/AN/A0 up, 1 downAug 8, 2022$25.59M
    Mar 31, 2022-$0.52-$0.43-$0.52 - -$0.36-20.93%MissN/A70 up, 0 downMay 9, 2022$22.44M
    Dec 31, 2021-$0.43-$0.39-$0.47 - -$0.33-10.26%MissN/A7N/AFeb 28, 2022$25.23M
    Sep 30, 2021-$0.48-$0.41-$0.46 - -$0.35-17.07%MissN/A70 up, 0 downNov 8, 2021$22.29M
    Jun 30, 2021-$0.42-$0.39-$0.44 - -$0.34-7.69%MissN/A8N/AAug 2, 2021$22.19M
    Mar 31, 2021-$0.37-$0.39-$0.44 - -$0.34+5.13%BeatN/A7N/AMay 3, 2021$20.44M
    Dec 31, 2020-$0.28-$0.30-$0.34 - -$0.26+6.67%BeatN/A7N/AMar 8, 2021$22.14M
    Sep 30, 2020-$0.33-$0.42-$0.42 - -$0.35+21.43%BeatN/A7N/ANov 2, 2020$20.37M
    Jun 30, 2020-$0.44-$0.63-$0.71 - -$0.60+30.16%BeatN/A7N/AAug 3, 2020$14.05M
    Mar 31, 2020-$0.47-$0.38-$0.41 - -$0.35-23.68%MissN/A6N/AMay 4, 2020$16.82M
    Dec 31, 2019-$0.36-$0.35-$0.40 - -$0.26-2.86%MissN/A7N/AMar 9, 2020$19.81M
    Sep 30, 2019-$0.46-$0.37-$0.39 - -$0.36-24.32%MissN/A4N/ANov 11, 2019$16.18M
    Jun 30, 2019-$0.35-$0.35-$0.42 - -$0.250.00%In lineN/A4N/AAug 6, 2019$16.32M
    Mar 31, 2019-$0.38-$0.25-$0.27 - -$0.24-52.00%MissN/A4N/AMay 8, 2019$14.99M
    Dec 31, 2018-$0.22-$0.21-$0.22 - -$0.20-4.76%MissN/A4N/AMar 7, 2019$15.62M
    Sep 30, 2018-$0.30-$0.28N/A-7.14%MissN/AN/AN/AOct 18, 2018$13.38M
    Jun 30, 2018-$0.19N/AN/AN/AN/AN/AN/AN/AAug 29, 2018$13.66M
    Mar 31, 2017-$0.30N/AN/AN/AN/AN/AN/AN/AJun 29, 2017$11.43M
    Last 35 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.44, after -$0.76 the year before. It was -$1.01 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.44N/A
    Dec 31, 2024-$0.76N/A
    Dec 31, 2023-$1.14N/A
    Dec 31, 2022-$1.79N/A
    Dec 31, 2021-$1.70N/A
    Dec 31, 2020-$1.52N/A
    Dec 31, 2019-$1.55N/A
    Dec 31, 2018-$1.01N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,900 words across 13 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,86113
    2026Q2Jun 30, 20265,81611
    2026Q1Mar 31, 20266,35112
    2025Q4Dec 31, 20256,10510
    2025Q3Sep 30, 20258,61212
    2025Q2Jun 30, 20257,51911
    2025Q1Mar 31, 20258,39610
    2024Q4Dec 31, 20247,39011

    2026Q3 Earnings Call

    Opening remarks

    Saqib Iqbal Vice President, FP&A and Investor Relations Earlier today, SI-BONE released financial results for the quarter ended September 30, 2026. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management's remarks today may include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, such as our most recent Form 10-K and Form 10-Q, and actual results may differ materially from any forward-looking statements that we make today. Accordingly, you should not place undue reliance on these statements. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements, except as required by law. During the call, management may also discuss certain non-GAAP measures, including adjusted EBITDA and free cash flow. Unless otherwise noted, any reference to profitability is in terms of positive adjusted EBITDA. For a reconciliation of these non-GAAP measures to GAAP accounting, please see the company's full earnings release issued earlier today. Unless otherwise noted, all results are compared to the comparable period in the prior year. With that, I'll turn the call over to Laura.

    Laura Francis CEO Thanks, Saqib. Good afternoon, and thank you for joining us. We delivered a solid third quarter with accelerating procedure demand, broader physician adoption and improving financial performance. These results reflect disciplined execution of our multiyear strategy to expand our differentiated platform into new clinical applications. By focusing on anatomy-specific solutions that enable durable fixation and fusion in patients with compromised bone, we're reaching more patients and expanding our growth opportunity. Worldwide revenue grew approximately 15% to $55.7 million. U.S. revenue increased approximately 14% to $52.8 million. U.S. procedure volume increased approximately 20%, supported by 16% growth in active physicians. The strong double-digit volume growth across all procedure types demonstrates that our targeted platform expansion and call point diversification strategies are delivering. In addition to the strong surgeon demand in the third quarter, demand accelerated for our expanded INTRA platform from interventional spine physicians in the office space and ASC sites of care. Our decision to build differentiated solutions with applications across all sites of care has made INTRA the preferred platform for this call point. International revenue grew 27% to $2.9 million, supported by continued adoption of technologies launched in the last 12 months. We converted the revenue growth into stronger financial performance. Adjusted EBITDA increased 32%, more than twice the pace of revenue growth, while working capital discipline contributed to stronger operating cash flow.

    Frequently Asked Questions About SIBN

    Did SIBN beat earnings estimates last quarter?

    Yes. Si-Bone reported EPS of -$0.08 for the quarter ended Sep 30, 2026, above the -$0.13 estimate, a 38.46% surprise.

    What EPS do analysts expect from SIBN next quarter?

    The consensus EPS estimate for Si-Bone for the quarter ending Dec 31, 2026 is -$0.07 from 11 analysts, with estimates from -$0.09 to -$0.05.

    How often does SIBN beat earnings estimates?

    Si-Bone beat the EPS estimate in each of the last 17 quarters, with an average surprise of +28.10%.